Madrigal appoints Jackie Fouse to Board; Fred Craves to retire in July 2025

MADRIGAL PHARMACEUTICALS, INC.

Fred Craves, Ph.D. resigns from Madrigal's Board effective July 1, 2025; no disagreement cited.
Board expanded to 10 members; Jacqualyn Fouse, Ph.D. elected to fill new vacancy on March 10, 2025.
Fouse to serve on Audit and Nominating & Governance Committees; receives annual cash retainer of $50,000 plus committee fees.
Fouse granted $600,000 equity award (50% options, 50% RSUs) vesting over two years; prorated annual director award also granted.
Fouse is former CEO of Agios Pharmaceuticals and current Chair of Agios Board; over 30 years healthcare experience.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Fred Craves

Director

MDGL · MADRIGAL PHARMACEUTICALS, INC.

Effective: 2025-07-01
Filed: March 11, 2025, 7:59 PM ET

On March 9, 2025, Fred Craves, Ph.D. provided notice of his resignation from the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), effective as of July 1, 2025.

Appointed

Jackie Fouse

Director

MDGL · MADRIGAL PHARMACEUTICALS, INC.

Effective: 2025-03-10
Filed: March 11, 2025, 7:59 PM ET

On March 10, 2025, following the recommendation of its Nominating and Governance Committee, the Board expanded the size of the Board from nine to ten members and elected Jackie Fouse, Ph.D. to fill the newly created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fred Craves resigned as Director at MADRIGAL PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

On March 9, 2025, Fred Craves, Ph.D. provided notice of his resignation from the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), effective as of July 1, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jackie Fouse was elected as Director at MADRIGAL PHARMACEUTICALS, INC..

Action: elected
Role: Director

Exact text from the filing

On March 10, 2025, following the recommendation of its Nominating and Governance Committee, the Board expanded the size of the Board from nine to ten members and elected Jackie Fouse, Ph.D. to fill the newly created vacancy.

View on SEC.gov

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-051461

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.